Dyspepsia

Current Opinion in Gastroenterology

Volumn 29, Issue 6, 2013, Pages 662-668

  Ford, Alexander C ^a,b   Moayyedi, Paul ^c  

^a LEEDS GENERAL INFIRMARY   (United Kingdom)

^b UNIVERSITY OF LEEDS   (United Kingdom)

^c MCMASTER UNIVERSITY   (Canada)

Author keywords

Antidepressant therapy; diet; dyspepsia; gut brain interactions; microbiome

Indexed keywords

ACOTIAMIDE; ARBACLOFEN; BUSPIRONE; CISAPRIDE; ITOPRIDE; PROBIOTIC AGENT; PROTON PUMP INHIBITOR; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT;

ACUPUNCTURE; DIGESTIVE SYSTEM INFLAMMATION; DYSPEPSIA; ERADICATION THERAPY; GASTROESOPHAGEAL REFLUX; HELICOBACTER PYLORI; HUMAN; INTESTINE FLORA; MEDICAL RESEARCH; NONHUMAN; PEPTIC ULCER; QUALITY OF LIFE; REVIEW; STOMACH FUNDOPLICATION; TREATMENT OUTCOME; UPPER GASTROINTESTINAL TRACT INFLAMMTION;

ANTIDEPRESSIVE AGENTS, TRICYCLIC; BENZAMIDES; DIET; DYSPEPSIA; GASTROESOPHAGEAL REFLUX; GASTROINTESTINAL AGENTS; HUMANS; PEPTIC ULCER; PROBIOTICS; THIAZOLES;

EID: 84886095276     PISSN: 02671379     EISSN: 15317056     Source Type: Journal    
DOI: 10.1097/MOG.0b013e328365d45d     Document Type: Review

References (73)

1. Marwaha A, Ford AC, Lim A, Moayyedi P. The worldwide prevalence of dyspepsia: systematic review and meta-analysis. Gastroenterology 2009; 136 (Suppl 1):A149.
2. Colin-Jones DG, Bloom B, Bodemar G, et al. Management of dyspepsia: report of a working party. Lancet 1988; 331:576-579. (Pubitemid 18060490)
3. Tack J, Talley NJ, Camilleri M, et al. Functional gastroduodenal disorders. Gastroenterology 2006; 130:1466-1479.
4. Mak AD, Wu JC, Chan Y, et al. Dyspepsia is strongly associated with major depression and generalised anxiety disorder: a community study. Aliment Pharmacol Ther 2012; 36:800-810.
5. Zhao Y, Zou D, Wang R, et al. Dyspepsia and irritable bowel syndrome in China: a population-based endoscopy study of prevalence and impact. Aliment Pharmacol Ther 2010; 32:562-572.
6. Vakil N, Halling K, Ohlsson L, et al. Symptom overlap between postprandial distress and epigastric pain syndromes of the Rome III dyspepsia classification. Am J Gastroenterol 2013; 108:767-774.
7. Ford AC, Marwaha A, Lim A, et al. What is the prevalence of clinically significant endoscopic findings in subjects with dyspepsia? Systematic review and meta-analysis. Clin Gastroenterol Hepatol 2010; 8:830-837.
8. Mahadeva S, Yadav H, Rampal S, et al. Ethnic variation, epidemiological factors and quality of life impairment associated with dyspepsia in urban Malaysia. Aliment Pharmacol Ther 2010; 31:1141-1151.
9. Ford AC, Forman D, Bailey AG, et al. Effect of dyspepsia on survival: a longitudinal 10-year follow-up study. Am J Gastroenterol 2012; 107:912-921.
10. Lacy BE, Weiser KT, Kennedy AT, et al. Functional dyspepsia: the economic impact to patients. Aliment Pharmacol Ther 2013; 38:170-177.
11. Ford AC, Qume M, Moayyedi P, et al. Helicobacter pylori 'test and treat' or endoscopy for managing dyspepsia? An individual patient data meta-analysis. Gastroenterology 2005; 128:1838-1844. (Pubitemid 40824695)
12. Ford AC, Moayyedi P, Jarbol DE, et al. Meta-analysis: Helicobacter pylori 'test and treat' compared with empirical acid suppression for managing dyspepsia. Aliment Pharmacol Ther 2008; 28:534-544.
13. Vakil N, Talley NJ, Veldhuyzen van Zanten S, et al. Cost of detecting malignant lesions by endoscopy in 2741 primary care dyspeptic patients without alarm symptoms. Clin Gastroenterol Hepatol 2009; 7:756-761.
14. Shawihdi M, Thompson E, Kapoor N, et al. Variation in gastroscopy rate in English general practice and outcome for oesophagogastric cancer: retrospective analysis of hospital episode statistics. Gut 2013. doi: 10.1136/gutjnl-2012- 304202.
15. Jun BY, Lim CH, Lee WH, et al. Detection of neoplastic gastric lesions using capsule endoscopy: pilot study. Gastroenterol Res Pract 2013. doi: 10. 1155/2013/730261.
16. Weinstein DH, Derijke S, Chow CC, et al. A new method for determining gastric acid output using a wireless pH-sensing capsule. Aliment Pharmacol Ther 2013; 37:1198-1209.
17. Donnellan C, Sharma N, Preston C, et al. Medical treatments for the maintenance therapy of reflux oesophagitis and endoscopic negative reflux disease. Cochrane Database Syst Rev 2005; CD003245.
18. Vakil NB, Huff FJ, Bian A, et al. Arbaclofen placarbil in GERD: a randomized, double-blind, placebo-controlled study. Am J Gastroenterol 2011; 106: 1427-1438.
19. Grant AM, Cotton SC, Boachie C, et al. Minimal access surgery compared with medical management for gastro-oesophageal reflux disease: five year follow-up of a randomised controlled trial (REFLUX). Br Med J 2013; 346:f1908.
20. Ford AC, Delaney BC, Forman D, et al. Eradication therapy for peptic ulcer disease in Helicobacter pylori positive patients. Cochrane Database Syst Rev 2006; CD003840.
21. Ford AC, Delaney BC, Forman D, et al. Eradication therapy in Helicobacter pylori positive peptic ulcer disease: systematic review and economic analysis. Am J Gastroenterol 2004; 99:1833-1855. (Pubitemid 39237517)
22. Tang CL, Ye F, Liu W, et al. Eradication of Helicobacter pylori infection reduces the incidence of peptic ulcer disease in patients using nonsteroidal anti-inflammatory drugs: a meta-analysis. Helicobacter 2012; 17:286-296.
23. Yeomans ND, Tulassay Z, Juhasz L, et al. A comparison of omeprazole with ranitidine for ulcers associated with nonsteroidal antiinflammatory drugs. Acid Suppression Trial: Ranitidine versus Omeprazole for NSAID-associated Ulcer Treatment (ASTRONAUT) Study Group. N Engl J Med 1998; 338: 719-726.
24. Agrawal NM, Campbell DR, Safdi MA, et al. Superiority of lansoprazole vs. ranitidine in healing nonsteroidal anti-inflammatory drug-associated gastric ulcers: results of a double-blind, randomized, multicenter study. NSAID-Associated Gastric Ulcer Study Group. Ann Intern Med 2000; 160: 1455-1461. (Pubitemid 30327448)
25. Moayyedi P, Soo S, Deeks J, et al. Pharmacological interventions for nonulcer dyspepsia. Cochrane Database Syst Rev 2006; CD001960.
26. Moayyedi P, Delaney BC, Vakil N, et al. The efficacy of proton pump inhibitors in nonulcer dyspepsia: a systematic review and economic analysis. Gastro-enterology 2004; 127:1329-1337. (Pubitemid 39457759)
27. Abraham NS, Moayyedi P, Daniels B, et al. The methodological quality of trials affects estimates of treatment efficacy in functional (nonulcer) dyspepsia. Aliment Pharmacol Ther 2004; 19:631-641. (Pubitemid 38445424)
28. Holtmann G, Talley NJ, Liebregts T, et al. A placebo-controlled trial of itopride in functional dyspepsia. N Engl J Med 2006; 354:832-840. (Pubitemid 43290921)
29. Talley NJ, Tack J, Ptak T, et al. Itopride in functional dyspepsia: results of two phase III multicentre, randomised, double-blind, placebo-controlled trials. Gut 2008; 57:740-746. (Pubitemid 351716964)
30. Moayyedi P, Soo S, Deeks JJ, et al. Systematic review and economic evaluation of Helicobacter pylori eradication treatment for nonulcer dyspepsia. Br Med J 2000; 321:659-664.
31. Mazzoleni LE, Sander GB, Francesconi CF, et al. Helicobacter pylori eradication in functional dyspepsia: HEROES trial. Arch Intern Med 2011; 171: 1929-1936.
32. Moayyedi P. Helicobacter pylori eradication for functional dyspepsia: what are we treating?: comment on 'Helicobacter pylori eradication in functional dyspepsia'. Arch Intern Med 2011; 171:1936-1937.
33. Ford AC, Moayyedi P. Managing dyspepsia. Curr Gastroenterol Rep 2009; 11:288-294.
34. Moayyedi P. Dyspepsia. Curr Opin Gastroenterol 2012; 28:602-607.
35. Kindt S, Van Oudenhove L, Mispelon L, et al. Longitudinal and cross-sectional factors associated with long-term clinical course in functional dyspepsia: a 5-year follow-up study. Am J Gastroenterol 2011; 106:340-348.
36. Mak AD, Wu JC, Chan Y, et al. Dyspepsia is strongly associated with major depression and generalised anxiety disorder: a community study. Aliment Pharmacol Ther 2012; 36:800-810.
37. Filipovic BF, Randjelovic T, Ille T, et al. Anxiety, personality traits and quality of life in functional dyspepsia-suffering patients. Eur J Intern Med 2013; 24:83-86.
38. Braak B, Booij J, Klooker TK, et al. The dopaminergic system in patients with functional dyspepsia analysed by single photon emission computed tomography (SPECT) and an alpha-methyl-para-tyrosine (AMPT) challenge test. Eur J Nucl Med Mol Imaging 2012; 39:642-650.
39. Zhou G, Qin W, Zeng F, et al. White-matter microstructural changes in functional dyspepsia: a diffusion tensor imaging study. Am J Gastroenterol 2013; 108:260-269.
40. Zanini B, Ricci C, Bandera F, et al. Incidence of post-infectious irritable bowel syndrome and functional intestinal disorders following a water-borne viral gastroenteritis outbreak. Am J Gastroenterol 2012; 107:891-899.
41. Porter CK, Gormley R, Tribble DR, et al. The incidence and gastrointestinal infectious risk of functional gastrointestinal disorders in a healthy US adult population. Am J Gastroenterol 2011; 106:130-138.
42. Ford AC, Thabane M, Collins SM, et al. Prevalence of uninvestigated dyspepsia 8 years after a large waterborne outbreak of bacterial dysentery: cohort study. Gastroenterology 2010; 138:373-378.
43. Simren M, Barbara G, Flint HJ, et al. Intestinal microbiota in functional bowel disorders: a Rome foundation report. Gut 2013; 62:159-176.
44. Liebregts T, Adam B, Bredack C, et al. Small bowel homing T cells are associated with symptoms and delayed gastric emptying in functional dyspepsia. Am J Gastroenterol 2011; 106:1089-1098.
45. Bercik P, De Giorgio R, Blennerhassett P, et al. Immune-mediated neural dysfunction in a murine model of chronic Helicobacter pylori infection. Gastroenterology 2002; 123:1205-1215.
46. Bercik P, Denou E, Collins J, et al. The intestinal microbiota affect central levels of brain-derived neurotropic factor and behavior in mice. Gastroenter-ology 2011; 141:599-609.
47. Farré R, Tack J. Food and symptom generation in functional gastrointestinal disorders: physiological aspects. Am J Gastroenterol 2013; 108:698-706.
48. Feinle-Bisset C, Azpiroz F. Dietary lipids and functional gastrointestinal disorders. Am J Gastroenterol 2013; 108:737-747.
49. Vazquez-Roque MI, Camilleri M, Smyrk T, et al. A controlled trial of gluten-free diet in patients with irritable bowel syndrome-diarrhea: effects on bowel frequency and intestinal function. Gastroenterology 2013; 144:903-911.
50. Carroccio A, Mansueto P, Iacono G, et al. Nonceliac wheat sensitivity diagnosed by double-blind placebo-controlled challenge: exploring a new clinical entity. Am J Gastroenterol 2012; 107:1908-1912.
51. Ford AC, Ching E, Moayyedi P. Meta-analysis: yield of diagnostic tests for coeliac disease in dyspepsia. Aliment Pharmacol Ther 2009; 30:28-36.
52. Ford AC, Marwaha A, Lim A, Moayyedi P. Systematic review and meta-analysis of the prevalence of irritable bowel syndrome in individuals with dyspepsia. Clin Gastroenterol Hepatol 2010; 8:401-409.
53. Tortora R, Russo I, De Palma GD, et al. In vitro gliadin challenge: diagnostic accuracy and utility for the difficult diagnosis of celiac disease. Am J Gastro-enterol 2012; 107:111-117.
54. Biesiekierski JR, Newnham ED, Irving PM, et al. Gluten causes gastrointestinal symptoms in subjects without celiac disease: a double-blind randomized placebo-controlled trial. Am J Gastroenterol 2011; 106:508-514.
55. Gibson PR, Shepherd SJ. Food choice as a key management strategy for functional gastrointestinal symptoms. Am J Gastroenterol 2012; 107:657-666.
56. Shepherd SJ, Lomer MC, Gibson PR. Short-chain carbohydrates and functional gastrointestinal disorders. Am J Gastroenterol 2013; 108:707-717.
57. Chang L, Adeyemo M, Karagiannidis I, et al. Serum and colonic mucosal immune markers in irritable bowel syndrome. Am J Gastroenterol 2012; 107:262-272.
58. Schmulson M, Chey WD. Abnormal immune regulation and low grade inflammation in IBS: does one size fit all? Am J Gastroenterol 2012; 107:273-275.
59. Chey WD. The role of food in the functional gastro intestinal disorders: introduction to a manuscript series. Am J Gastroenterol 2013; 108:694-697.
60. Jeffery IB, O'Toole PW. Diet-microbiota interactions and their implications for healthy living. Nutrients 2013; 5:234-252.
61. Lacy BE, Talley NJ, Locke GR 3rd, et al. Review article: current treatment options and management of functional dyspepsia. Aliment Pharmacol Ther 2012; 36:3-15.
62. Ford AC, Talley NJ, Schoenfeld PS, et al. Efficacy of antidepressants and psychological therapies in irritable bowel syndrome: systematic review and meta-analysis. Gut 2009; 58:367-378.
63. Wu JC, Cheong PK, Chan Y, et al. A randomized, double-blind, placebo-controlled trial of low dose imipramine for treatment of refractory functional dyspepsia. Gastroenterology 2011; 140 (Suppl 1):S50.
64. Talley NJ, Locke GR 3rd, Herrick LM, et al. Functional Dyspepsia Treatment Trial (FDTT): a double-blind, randomized, placebo-controlled trial of anti-depressants in functional dyspepsia, evaluating symptoms, psychopathology, pathophysiology and pharmacogenetics. Contemp Clin Trials 2012; 33: 523-533.
65. Locke GR, Bouras EP, Howden CW, et al. The functional dyspepsia treatment trial (FDTT) key results. Gastroenterology 2013; 144 (Suppl 1):S140.
66. Kusunoki H, Haruma K, Manabe N, et al. Therapeutic efficacy of acotiamide in patients with functional dyspepsia based on enhanced postprandial gastric accommodation and emptying: randomized controlled study evaluation by real-time ultrasonography. Neurogastroenterol Motil 2012; 24:540-545.
67. Matsueda K, Hongo M, Tack J, et al. A placebo-controlled trial of acotiamide for meal-related symptoms of functional dyspepsia. Gut 2012; 61:821-828.
68. Van Oudenhove L, Kindt S, Vos R, et al. Influence of buspirone on gastric sensorimotor function in man. Aliment Pharmacol Ther 2008; 28:1326-1333.
69. Tack J, Janssen P, Masaoka T, et al. Efficacy of buspirone, a fundus-relaxing drug, in patients with functional dyspepsia. Clin Gastroenterol Hepatol 2012; 10:1239-1245.
70. Ma TT, Yu SY, Li Y, et al. Randomised clinical trial: an assessment of acupuncture on specific meridian or specific acupoint vs. sham acupuncture for treating functional dyspepsia. Aliment Pharmacol Ther 2012; 35:552-561.
71. Zeng F, Qin W, Ma T, et al. Influence of acupuncture treatment on cerebral activity in functional dyspepsia patients and its relationship with efficacy. Am J Gastroenterol 2012; 107:1236-1247.
72. Moayyedi P, Ford AC, Talley NJ, et al. The efficacy of probiotics in the therapy of irritable bowel syndrome: a systematic review. Gut 2010; 59:325-332.
73. Ford AC, Forman D, Bailey AG, et al. Who consults with dyspepsia? Results from a longitudinal 10-yr follow-up study. Am J Gastroenterol 2007; 102:957-965. (Pubitemid 46698219)